Can I Take L-Theanine With MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Take It?

MK-677 is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile release of growth hormone (GH) and, secondarily, insulin-like growth factor 1 (IGF-1). It was originally developed by Merck as a potential treatment for GH deficiency and age-related muscle loss, but it never received FDA approval for any clinical indication.

Mechanism of GH Release

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor activated by ghrelin, the endogenous "hunger hormone." This binding triggers the pituitary to release GH in a pulsatile pattern that broadly resembles physiological secretion. A 2-year randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=65, healthy older adults) found that 25 mg ibutamoren daily increased IGF-1 by approximately 39% vs placebo and improved lean body mass without significant changes in fat mass at 12 months 1.

Why Users Layer In Sleep and Anxiety Supplements

Because GH secretion peaks during slow-wave sleep, many MK-677 users take their dose at night. Vivid dreaming and early-morning restlessness are among the most frequently reported subjective complaints in online registries and case series. That side-effect profile is exactly why L-theanine appears in MK-677 stacks: users seek a mild anxiolytic that will not suppress GH release the way benzodiazepines do.

A crossover study (N=14) published in Biological Psychology confirmed that a single 200 mg L-theanine dose produced measurable alpha-wave activity on EEG within 40 minutes of ingestion, consistent with a relaxed-but-alert mental state 2. That neurological signature is qualitatively different from sedation, which is a meaningful distinction for anyone concerned about blunting GH-pulsatile secretion overnight.

How Does L-Theanine Work?

L-theanine (gamma-glutamylethylamide) is a non-protein amino acid found almost exclusively in tea leaves (Camellia sinensis). At doses used by humans (100 to 400 mg), it crosses the blood-brain barrier and modulates several neurotransmitter systems simultaneously.

Neurotransmitter Targets

L-theanine antagonizes glutamate NMDA and AMPA receptors, reducing excitatory tone. It also increases brain concentrations of GABA, serotonin, and dopamine in animal studies, though direct human neuroimaging confirmation at low doses is still limited 3. Critically, it does not appear to directly suppress the hypothalamic-pituitary axis at typical oral doses.

Effect on Sleep Architecture

A double-blind, placebo-controlled trial in boys with ADHD (N=98, ages 8 to 12) found that 400 mg L-theanine daily for 6 weeks significantly improved sleep efficiency (p<0.05) and reduced nighttime activity without causing next-day sedation 4. An adult crossover study published in Nutrients (N=30) similarly found that 200 mg L-theanine before bed improved self-reported sleep quality scores by 13.9% vs placebo without altering polysomnographic REM percentage 5.

These data suggest L-theanine improves subjective sleep quality without meaningfully disrupting the sleep architecture in which GH secretion occurs. That is the core reason the combination with MK-677 is considered low-risk among clinicians who supervise research compound use.

Is There a Pharmacokinetic Interaction Between MK-677 and L-Theanine?

No pharmacokinetic interaction has been documented. MK-677 and L-theanine are metabolized through entirely separate pathways.

MK-677 Metabolism

Ibutamoren is metabolized primarily via hepatic oxidation, with CYP3A4 playing a minor role based on in-vitro data from early Merck pharmacology reports 6. Its oral bioavailability is approximately 60 to 70%, and its half-life is roughly 24 hours, which supports once-daily dosing.

L-Theanine Metabolism

L-theanine is hydrolyzed in the small intestine and the liver to ethylamine and glutamic acid. It does not meaningfully induce or inhibit CYP450 enzymes at standard oral doses based on in-vitro hepatocyte screening data 7. Peak plasma concentration occurs 30 to 60 minutes after ingestion, and it is cleared within 3 to 5 hours.

Because these two compounds share no overlapping metabolic enzymes and neither inhibits the other's absorption or clearance, the interaction classification is purely pharmacodynamic.

Pharmacodynamic Interaction: What Actually Happens When You Take Both?

The pharmacodynamic interaction is additive at the level of CNS calming, but it does not appear to generate any clinically dangerous effect at typical doses.

Shared Calming Pathway

MK-677 raises GH and IGF-1. Neither of those hormones is sedating in the conventional sense. However, the ghrelin receptor is expressed in limbic regions, and ghrelin agonism has mild anxiogenic properties in some animal models 8. L-theanine counters this by reducing glutamatergic excitation. The net result reported by most users is a subjectively calmer transition to sleep without feeling "knocked out."

Cortisol Modulation

MK-677 can modestly increase cortisol, particularly in the early weeks of use. A 2-week Phase I study found a 23% mean increase in 24-hour urinary cortisol in healthy young men taking 25 mg ibutamoren daily 9. L-theanine, by contrast, attenuated cortisol and chromogranin A responses to a mental stress task in a small double-blind crossover study (N=12) 10. Taking both compounds together may therefore partially offset ibutamoren's cortisol-raising effect. This is not an adverse interaction; many clinicians would consider it a benefit.

Risk of Over-Sedation

At standard doses (MK-677 at 10 to 25 mg and L-theanine at 100 to 400 mg), over-sedation is not a documented outcome in any published study or formal case report. The theoretical risk increases if L-theanine is stacked with additional GABAergic supplements such as magnesium glycinate, valerian root, or prescription sleep aids. Adding MK-677 to that already-sedating combination does not independently raise risk, but the total supplement burden warrants physician review.

Dosing, Timing, and Practical Guidance

Getting timing right matters more than most users expect. Here is a practical framework developed by the HealthRX medical team for patients who are already using, or considering, both compounds under physician supervision.

Recommended Timing Window

Take MK-677 and L-theanine together 30 to 60 minutes before bed. This timing aligns MK-677's first GH pulse with the early stages of slow-wave sleep, which typically begins 60 to 90 minutes after sleep onset. L-theanine's peak plasma concentration (30 to 60 minutes post-ingestion) overlaps with the pre-sleep window, supporting a calm transition into slow-wave sleep without lingering morning sedation.

Starting Doses

| Compound | Starting Dose | Common Research Dose | Notes | |---|---|---|---| | MK-677 | 10 mg nightly | 25 mg nightly | Titrate slowly; higher doses increase water retention | | L-theanine | 100 mg nightly | 200 mg nightly | Up to 400 mg studied safely in trials |

The FDA's Generally Recognized As Safe (GRAS) notice for L-theanine (GRN 000209) covers doses up to 250 mg per serving, providing at least a regulatory reference point for the supplement side of this stack 11.

Adjusting for Caffeine Users

Many people take L-theanine specifically to blunt caffeine's anxiogenic properties during the day. A meta-analysis of 11 randomized trials published in Nutrition Reviews found that the 2:1 L-theanine-to-caffeine ratio (e.g., 200 mg theanine + 100 mg caffeine) improved attention and reduced headache scores vs caffeine alone 12. If you use this combination during the day, that daytime L-theanine dose is cleared before your evening MK-677 administration and does not compound the nighttime dose.

What Labs Should You Monitor While Using Both?

MK-677 is not a benign vitamin supplement. Ongoing lab monitoring is standard in any responsible clinical protocol.

Core Panel Every 3 to 6 Months

• IGF-1 (serum). Target the upper third of the age-adjusted reference range, not above it. Sustained IGF-1 supraphysiological levels are associated with increased cancer risk in observational data 13.
• Fasting glucose and HbA1c. MK-677 causes mild insulin resistance. The Phase I data cited above showed a 0.3 mmol/L mean increase in fasting glucose at 25 mg for 2 weeks 9.
• Cortisol (AM serum). As noted, ibutamoren modestly raises cortisol. Patients with pre-existing HPA axis dysfunction need closer monitoring.
• Lipid panel. GH influences lipolysis; individual responses to IGF-1 elevation vary.

L-theanine does not require dedicated lab monitoring at standard doses. No hepatotoxic signal has appeared in the published human safety literature 3.

Guideline Position on GH Secretagogues

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against the use of GH secretagogues outside of controlled research settings in adults without a confirmed diagnosis of GH deficiency" 14. This position does not change based on what supplements accompany ibutamoren.

Who Should Avoid This Combination?

Certain populations face elevated risk from MK-677 regardless of what supplements accompany it.

Absolute Cautions for MK-677 Use

• Active or prior malignancy. IGF-1 is a mitogenic signal. The Endocrine Society guideline explicitly lists active malignancy as a contraindication to GH and GH secretagogue therapy 14.
• Type 1 or Type 2 diabetes. Insulin resistance worsened by MK-677 can destabilize glycemic control. The American Diabetes Association Standards of Care note that GH excess states reliably impair glucose tolerance 15.
• Pediatric users. MK-677 has not been studied in minors outside of a single pediatric short-stature trial, and growth plate interactions are a theoretical concern.
• Pregnancy and lactation. No human safety data exist. Avoid entirely.

Cautions Specific to L-Theanine

L-theanine's safety profile is favorable. The only population-level caution worth noting is concurrent use with antihypertensive medications: one small crossover study found an additive blood-pressure-lowering effect (5 mmHg mean systolic reduction vs placebo) at 200 mg 16. Patients already on antihypertensives should disclose L-theanine use to their prescribing physician.

What Do Clinicians Say About This Combination?

The clinical evidence base for off-label MK-677 use is thin by FDA standards. Physicians who work in longevity or hormone-optimization medicine nonetheless encounter this question regularly.

The Endocrine Society's 2019 GH deficiency guideline authors wrote that secretagogues "increase IGF-1 concentrations into the normal young-adult range and may have favorable effects on body composition, but long-term safety data remain insufficient to support routine clinical use" 14. That measured language reflects the evidence gap rather than a finding of harm.

For L-theanine specifically, a 2020 review in Nutrients (Hidese et al.) concluded that L-theanine at 200 to 400 mg/day produced "significant improvements in stress and anxiety-related symptoms without notable adverse effects" across multiple randomized trials 17. Stacking it with a GH secretagogue does not change that assessment, because L-theanine's mechanism operates independently of the GH axis.

Practical Checklist Before Starting This Stack

Run through all five points with a physician before your first dose.

1. Confirm MK-677 source and purity. Third-party certificates of analysis (CoA) from an ISO 17025-accredited lab are the minimum standard. Contamination with anabolic steroids or prohormones has been documented in research compound products 18.
2. Get baseline labs. IGF-1, fasting glucose, HbA1c, cortisol (AM), and a lipid panel before starting.
3. Start MK-677 at 10 mg, not 25 mg. Most of the dose-dependent side effects (edema, joint pain, morning fatigue) are meaningfully reduced at 10 mg, and IGF-1 still rises into the upper reference range for most adults.
4. Cap L-theanine at 200 mg nightly until you assess your individual response. There is no incremental sleep benefit documented above 400 mg, and going higher just broadens the interaction risk window with other supplements.
5. Recheck labs at 6 to 8 weeks. IGF-1 and fasting glucose are the priority signals. Adjust dose based on those results, not on subjective outcomes alone.

The American Association of Clinical Endocrinology (AACE) Growth Hormone Task Force recommends IGF-1 be maintained within the age- and sex-adjusted reference range for all GH axis interventions 19.